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Abstract
Introduction: The continual reassessment method (CRM) is a model-based design for phase I trials, which aims to
find the maximum tolerated dose (MTD) of a new therapy. The CRM has been shown to be more accurate in
targeting the MTD than traditional rule-based approaches such as the 3 + 3 design, which is used in most phase I
trials. Furthermore, the CRM has been shown to assign more trial participants at or close to the MTD than the 3 + 3
design. However, the CRM’s uptake in clinical research has been incredibly slow, putting trial participants, drug
development and patients at risk. Barriers to increasing the use of the CRM have been identified, most notably a
lack of knowledge amongst clinicians and statisticians on how to apply new designs in practice. No recent tutorial,
guidelines, or recommendations for clinicians on conducting dose-finding studies using the CRM are available.
Furthermore, practical resources to support clinicians considering the CRM for their trials are scarce.
Methods: To help overcome these barriers, we present a structured framework for designing a dose-finding study
using the CRM. We give recommendations for key design parameters and advise on conducting pre-trial simulation
work to tailor the design to a specific trial. We provide practical tools to support clinicians and statisticians, including
software recommendations, and template text and tables that can be edited and inserted into a trial protocol. We also
give guidance on how to conduct and report dose-finding studies using the CRM.
Results: An initial set of design recommendations are provided to kick-start the design process. To complement these
and the additional resources, we describe two published dose-finding trials that used the CRM. We discuss their designs,
how they were conducted and analysed, and compare them to what would have happened under a 3 + 3 design.
Conclusions: The framework and resources we provide are aimed at clinicians and statisticians new to the CRM design.
Provision of key resources in this contemporary guidance paper will hopefully improve the uptake of the CRM in phase I
dose-finding trials.
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Background
Phase I trials are conducted to find the maximum toler-
ated dose (MTD) of a new drug or treatment. The MTD
is defined as “…the dose expected to produce some
degree of medically unacceptable dose-limiting toxicity…
in a specified proportion…of patients” [1]. The “specified
proportion” in this definition is commonly known as the
target toxicity level (TTL).
Most phase I trials use rule-based approaches, such as
the 3 + 3 design [2, 3], to identify the MTD [4, 5]. Under
the 3 + 3 design, cohorts of three patients are assigned
to increasing dose levels until one or more dose-limiting
toxicities (DLTs) is observed. If one out of three patients
has a DLT, a further three patients are assigned to the
current dose. If two or more patients out of three or six
patients at the current dose experience a DLT, the trial
is terminated and the dose below this level is declared
the MTD. The 3 + 3 design uses only data at the current
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dose to choose the next dose and MTD, resulting in un-
certainty around the estimated DLT risks at each dose.
Furthermore, as no TTL is specified by investigators
when using the 3 + 3 design, the identified MTD often
has a true risk of causing severe toxicity far different to
what clinicians may deem acceptable for the treatment
under investigation. These and other drawbacks in rule-
based designs have been identified and reported [6, 7].
The Medical Research Council (MRC) Network of Hubs
for Trials Methodology Research’s Adaptive Designs
Working Group published a short note on why the 3 +
3 design, and A + B designs in general, should not be
used for dose-finding studies. They provide guidance on
better designs and software for conducting dose-finding
studies [8].
Model-based designs are an alternative to rule-based
designs [9]. They use a statistical model to estimate the
relationship between dose and DLT risk, which then
informs dose escalation decisions. The model is also
used to identify the MTD, which is defined relative to a
TTL explicitly specified by investigators before the trial.
The most well-known model-based design is the continual
reassessment method (CRM) [10]. The CRM combines all
available trial data, with available information from clini-
cians and past trials, to estimate the MTD. Many studies
have compared the CRM to the 3 + 3 design and found that
the CRM is more likely to recommend the correct MTD
and dose more trial patients close to the MTD [11–15].
Although first proposed nearly 30 years ago, the uptake
of the CRM in mainstream clinical research has been un-
fortunately slow [3–5, 16]. Garrett-Mayer [17] published a
tutorial paper on the CRM, which described the design
and used two simulated trials to illustrate how studies
may be conducted. Since then, the landscape has changed:
a handful of trials have used the CRM in practice [5]; new
software has been developed; further recommendations
have been provided, based on both theoretical research
and practical experience [18, 19]; and regulatory agencies
have updated guidance documents to explicitly mention
adaptive designs for clinical trials [20, 21]. Several barriers
to the implementation of the CRM have been formally
identified too. These include a lack of expertise, both in
the clinical and statistical communities, a lack of user-
friendly software, and a fear that recommendations from a
model-based design cannot be overridden by clinicians
[22–24]. To help overcome these barriers and provide
up-to-date resources for investigators, we detail how to
design and conduct a phase I dose-finding study using the
CRM. We describe the key components of the CRM, illus-
trate a framework to structure the design process, and list
the decisions the trial team should make. We provide rec-
ommendations for fine-tuning the design and describe
available software to assist clinicians and statisticians in
doing this. We also provide text and tables that can be
customised and inserted into a trial protocol. We con-
clude by illustrating two real dose-finding trials that used
the CRM, describing how they were designed and con-
ducted, and compare their performance to the traditional
3 + 3 design.
Methods
Here we describe and discuss the key parameters that
are needed to set up and run a CRM trial. These are:
Number of doses; Target Toxicity Level; Dose-toxicity
model; Dose-toxicity skeleton; Method of inference;
Decision rules; Sample size and cohort size; Safety
modifications; and Stopping rules.
Number of doses
Statistical and practical considerations underlie the choice
of how many and which doses to study. The most import-
ant statistical consideration is whether the doses and dose
range under investigation are likely to allow an accurate
MTD estimate. Figure 1 shows how different dose range
choices affect MTD selection under the same dose-tox-
icity relationship. Too few doses may mean the MTD will
be poorly estimated, whereas too many doses can hin-
der dose escalation towards the MTD.
Which doses are investigated in a trial is often deter-
mined by practical restrictions. For oral treatments, for
example, dose levels may increase based on number of
tablets. If the treatment is produced specifically for the
study (as in first-in-man studies), finances may limit
how many dose levels can be manufactured. However,
techniques such as allometric scaling can be used to
choose which doses should be studied [25]. In a review
of 197 phase I trials published between 1997 and 2008,
the median number of dose levels explored was five
(range 2–12) [26].
Target toxicity level
The acceptable chance of a patient experiencing a DLT
(the TTL) must be set before the trial starts. The TTL
depends on the disease, treatment under investigation,
availability of alternative treatment options, patients’
performance status, and likely associated adverse events
included in the definition of DLT. The TTL is determined
by clinical expertise, evidence from previous studies, and
guidance from the trial statistician. Often the TTL is set
between 20 and 35%, but some studies have set the TTL
as high as 40% [27, 28].
Dose-toxicity model
We need to state how we will model the relationship
between dose and the risk of observing a DLT. The
dose-toxicity model describes the probability of a patient
experiencing a DLT at a given dose (the dose-toxicity
relationship). The model is a fixed mathematical
Wheeler et al. BMC Medical Research Methodology           (2019) 19:18 Page 2 of 15
function that is monotonically increasing in dose, i.e. as
the dose increases, so does the probability of observing a
DLT. The model is written as F(β, d), where F(·,·) is the
chosen dose-toxicity function (see Table 1), β is a vector
of one or more parameters that alters the shape of the
dose-toxicity relationship, and d is the dose label for a
particular drug dose. Figure 2 shows some dose-toxicity
relationships for different function choices and parameter
values.
Dose-toxicity skeleton
Selecting a model for the dose-toxicity relationship can seem
daunting at first. However, we can ensure our chosen model
has a sensible shape over the dose levels of interest by
specifying a skeleton. The skeleton is the set of expected
DLT probabilities at the dose levels of interest and is speci-
fied by one or more clinicians before the trial. For a trial
with k dose levels, the clinical team specifies a prior average
estimate for the probability of DLT at each dose. These are
denoted here as p1, …, pk (the skeleton), and are only con-
strained to be monotonically increasing and distinct from
one another. For dose-toxicity model F(·,·), the dose label for
the ith dose is then di, such that pi = F(β*, di). Here, β* can
be the prior mean or median of the model parameter β.
Using dose labels ensures the model fits the skeleton well
before the trial; the actual dose scale of the drug does not
matter. Common model choices, prior reference values, and
resultant dose labels are given in Table 1. An example
Fig. 1 Number and spacing of doses for a dose-finding trial. The doses in Fig. 2(a) are too low to estimate the MTD, whereas those in Fig. 2(b)
are too high. In Fig. 2(c), the target dose lies between two dose levels, so patients will be assigned alternately to an overdose level and an
underdose level; the final MTD will likely be at one of these levels. Figure 2(d) illustrates a situation with several dose levels available in the region
of the MTD.
Table 1 Common choices for dose-toxicity models and resultant dose labels for the CRM
Model name Model (F(β, d)) General form of dose labels (di) Choice of β* (prior mean or median) Dose labels given β* (di)
Power (empiric) dexp(β)
p
1
expðβÞ
i
β = 0 pi
One-parameter logistic expð3þ exp ðβÞ dÞ
1þ expð3þ exp ðβÞ dÞ
ln ð pi1−piÞ−3
expðβÞ
β = 0 ln ð pi1−piÞ−3
Two-parameter logistic expðβ1þ exp ðβ2Þ dÞ
1þ expðβ1þ exp ðβ2Þ dÞ
ln ð pi1−piÞ−β1
expðβ2Þ
β1 = 0, β2 = 0 ln ð pi1−piÞ
Notation: pi = skeleton probability of DLT at i
th dose level; di = dose label for for i
th dose level
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Fig. 2 Dose-toxicity relationships for different dose-toxicity functions with varying parameter values
Fig. 3 Example of transforming drug-specific doses to dose labels using prior skeleton probabilities of DLT risk. Two-parameter logistic model
with prior average parameter values β1 = 2 and β2 = 1 (see Table A1 in Additional file 1: Appendix A for calculations).
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transformation from drug-specific doses to dose labels
is shown in Fig. 3 (calculations given in Table A1
(Additional file 1: Appendix A)).
Ultimately, the choice of model and skeleton are not
unique, as different pairings of dose-toxicity model and
skeleton can lead to identical dose-escalation recom-
mendations after a given sequence of observations [18].
With regards to the one-parameter logistic model, the
value of the fixed intercept (set to 3 in Table 1) does not
affect the shape of the dose-toxicity model. However, the
value of the fixed intercept affects the resultant dose
labels and the credible intervals. In designing a trial of
capecitabine in combination with epirubicin and cyclo-
phosphamide in patients with advanced breast cancer,
Morita [29] showed that changing the value of the inter-
cept shifted the greatest uncertainty in DLT risk from
the lowest dose to the highest dose. Therefore, if using
the one-parameter logistic model, the intercept can be
chosen to give prior uncertainties around dose levels
that matches clinical expectations.
Several papers have investigated how the number of
model parameters affects a CRM design’s theoretical prop-
erties and operating characteristics, including the chance of
estimating each dose as the MTD, percentage of patients al-
located to each dose level, average sample size, and average
proportion of patients who will experience a DLT [30–33].
Using a one- or two-parameter model affects how strongly
data at lower doses influence the next dose choice. A
one-parameter model is more likely to make recommenda-
tions that lead to faster escalation through the doses, result-
ing in a more efficient trial, but put participants at
higher risk of experiencing DLTs. A two-parameter
model is likely to better estimate the shape of the entire
dose-toxicity relationship [34], but less efficiently iden-
tify the MTD; it may take longer to reach the MTD since
two parameters must be estimated, and there may be diffi-
culties fitting the model or obtaining consistent estimates
of model parameters [31].
Although we cannot know the true shape of the
dose-toxicity relationship, the dose recommendations
made after each cohort will get closer to the MTD.
Certainly with a one-parameter model, we will reach
a reliable estimate of the MTD (and its probability of
DLT), even if our estimates for doses further away
are inaccurate. This result is insensitive to the model
and dose labels used [35], although the skeleton prob-
abilities should be spaced reasonably well apart. A
skeleton with prior DLT probabilities too close to-
gether will lead to slower dose escalation, and a skel-
eton with prior DLT probabilities too far apart will
lead to poor convergence towards the MTD [18]. Lee
and Cheung [36] and Cheung [18] proposed choosing
a skeleton by specifying the TTL and an indifference
interval. This is a probability interval within which
the clinician is happy for the DLT probability of the
MTD to fall. For example, a TTL of 25%, give or take
5%, gives an indifference interval of [20, 30%]. An ex-
ample of choosing a skeleton using the indifference
interval approach is given in Additional file 1: Appen-
dix B.
Once the number of dose levels, the TTL, dose-tox-
icity model and skeleton have been specified, other com-
ponents of the trial design can be discussed.
Inference
To make decisions by combining accruing trial data and
other evidence, we must state how we intend to make
statistical inferences on the model parameter(s), and
therefore the estimated DLT probability at each dose.
A likelihood-based approach can be used; the model
parameter(s) (denoted β previously) are estimated by
applying maximum likelihood methods to the trial
data. All major statistical software packages can per-
form these analyses. Maximum likelihood methods
can only be used with heterogeneous response data
(i.e., at least one DLT and one non-DLT response) to
calculate parameter estimates [35]. To obtain hetero-
geneous response data, the design is split into two
stages. Individual patients, or small cohorts of pa-
tients, are sequentially assigned to increasing dose
levels until the first DLT is observed. The likelihood
model-based design then takes over; a maximum like-
lihood estimate of the model parameter is used to up-
date the estimated DLT probabilities [37].
Another approach is to use Bayesian inference. A prior
probability distribution is assigned to the model parame-
ter(s), which translates to assigning a prior belief (and some
uncertainty) to the probability of DLT at each dose. Prior
beliefs and uncertainties can be derived from different
information sources, such as pre-clinical work, clinical
opinion [29, 38] and data from previous trials [39]. Where
relevant prior data are unavailable, appropriate vague priors
can be used [40–42]. If each dose is considered equally
likely to be the MTD before the trial, a “least informative”
prior can be obtained to reflect this belief [40].
Data from patients in the trial are used to update
the prior distribution on the model parameter(s),
which then gives a posterior distribution for the
model parameter(s) and therefore posterior beliefs for
the probability of DLT at each dose. These posterior
probabilities are used to make dose escalation deci-
sions. By assessing a design’s operating characteristics
with a specific prior in a variety of scenarios, the
prior distribution can be recalibrated until the model
makes recommendations for dose escalations and the
MTD that the trial team are happy with [43, 44]. This
iterative process helps ensure the design is appropri-
ately configured for the trial.
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Decision rules
Under a CRM approach, we do not assign the next
patient(s) to a dose level based only on the proportion
of patients with DLTs at the current dose level. Using a
model allows borrowing of information across dose
levels. We learn more about the toxicity risk of other
dose levels based on accrued data, which improves trial
efficiency. We may adapt the dose for the next patient
or cohort by estimating the probability of DLT for each
dose level, whether from a likelihood-based or Bayesian
approach, and then choosing the dose level using a spe-
cified decision rule. Possible decision rules include
choosing the dose with an estimated probability of DLT
closest to the TTL or, more conservatively, choosing
the dose with an estimated probability of DLT closest
to, but not greater than, the TTL. The first option al-
lows quicker escalation towards the true MTD, but may
expose more patients to overdoses. The second option
reduces the chance of overdosing patients, but may
take longer to escalate towards the true MTD.
Sample size and cohort size
Planned sample sizes in phase I trials are generally
dictated by practical constraints, such as the number
of centres, projected recruitment rates, and number of
dose levels, rather than statistical constraints related
to type I error rate or minimum power for testing a
specific hypothesis. Cheung [45] proposed formulae
that use a target average percentage of correctly
selecting the MTD (say, 50% of the time) to obtain a
lower bound for the trial sample size. We can then use
simulations to assess the design’s operating character-
istics with the sample size fixed at this lower bound,
and revise the sample size if necessary. We suggest
specifying a lower bound based on Cheung’s work and
a practical upper bound in grant applications and trial
protocols.
Once a reasonable sample size has been specified,
investigators can decide how many patients should be
dosed at each recommended dose before a
dose-escalation decision is made; this is called the co-
hort size. A cohort size of one patient will provide bet-
ter operating characteristics than dosing several
patients simultaneously at a dose level, although the
latter can reduce the trial duration [46] and still per-
form better than the 3 + 3 design [47]. Regulatory re-
quirements may also affect cohort sizes. For example,
we may be required to observe safety data from the
first patient before dosing other patients in that co-
hort. Following the recent phase I trial disasters of
TeGenero’s monoclonal antibody TGN1412 and Bial’s
fatty acid amide hydrolase inhibitor BIA 10–2474,
measures for monitoring patients must be in place if
cohorts of two or more patients are used [48, 49].
Safety modifications
Modifications to trial designs and dose-escalation rules
can easily be made to prevent overdosing patients and en-
sure a trial design has sensible operating characteristics.
For example, the original CRM approach proposed dosing
the first patient at the prior MTD guess, but many trialists
propose dosing the first patient at a level lower than this
(possibly even the lowest [47]). For the Viola trial [50],
which used the CRM to find the MTD of lenalidomide
and azacitidine in patients with relapsed acute myeloid
leukemia post allogenic stem cell transplant, the middle
(fourth) of seven possible doses was considered to be the
prior MTD. However, the study team chose to start at the
dose below this level (third) [51]. Some have suggested
not skipping untested dose levels when escalating to re-
duce the number of patients exposed to toxic doses [47,
52–54]. Faries [52] also enforced coherent dose-escalation:
if the last patient had a DLT, the next patient would not
receive a dose higher than that of the last patient, even if
the model recommended it. Under most trial setups of the
CRM, coherence is guaranteed [55], though this should be
checked in simulations.
Stopping rules
We need to state criteria for stopping the trial before
the maximum number of patients have been treated.
Early termination can be considered if the MTD is
judged to be outside the planned set of doses (i.e., all
doses are too toxic or all doses have a probability of
a DLT well below the TTL), or if adding more pa-
tients into the trial is unlikely to yield information
that would change the current MTD estimate [56]. In-
vestigators may stop a trial if either: a fixed number of pa-
tients have been consecutively dosed at one dose level
[49]; the estimated probability of all dose levels having a
DLT rate above (or below) the TTL is at least 90% [57,
58]; the width of the likelihood-based confidence interval
or Bayesian credible interval for the MTD reaches a par-
ticular level [10]; the probability that the next m patients
to be dosed in the trial will be given the same dose level,
regardless of DLT outcomes observed, exceeds some level
(e.g., 90%) [10, 56, 59]; or any combination of these [54]. If
stopping a trial after a fixed number of patients, the num-
ber should be chosen based on some probabilistic criter-
ion, e.g. if 10 consecutive patients receive the same dose
level, then we are at least 90% certain that the current
dose is the MTD. Therefore, using probabilistic ap-
proaches for early termination, or justifying other stopping
rules using probabilities, is encouraged. In the Viola trial,
the trial would be stopped early for toxicity if the chance
that the risk of DLT at the lowest dose was at least 10%
above the TTL exceeded 72%; this was tailored based on
the clinicians’ wishes to stop the trial if they saw an unex-
pected number of DLTs at the lowest dose [51].
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Evaluating designs by simulation
Once an initial setup for the design has been speci-
fied according to the parameters above, we need to
understand a design’s operating characteristics under
different dose-toxicity scenarios. This is best achieved
by the trial statistician simulating many trials under
each scenario. The objectives of these simulation
studies are to:
 demonstrate that a design has satisfactory operating
characteristics by the trial team’s standards, or give
results that the trial team can use to discuss and
modify the design;
 form a comprehensive comparison of alternative
designs, including the 3 + 3 design and a benchmark
design [60];
 clearly identify the best parameter choices;
 justify the sample size; and
 give information for use in grant applications and
the protocol.
The operating characteristics assessed should include the
probability of selecting each dose as the MTD, number/
proportion of patients given each dose, number of DLTs
per dose and in total, expected sample size, and expected
study duration.
The dose-toxicity scenarios used in the simulation
study should include: scenarios where each dose is in
fact the MTD; two extreme scenarios, in which the lowest
dose is above the MTD and the highest dose is below the
MTD; and any others that clinicians believe are plausible.
It is worthwhile considering unlikely but extreme scenarios
(e.g., first few doses are far below the MTD, then next
highest far above the MTD) to see how the trial design
behaves. For designing the CHARIOT trial, Frangou et al.
[61] considered true dose-toxicity curves over six dose
levels (schedules), which included scenarios where the
TTL of 25% was found at an exact dose, or was located
between two dose schedules. Brock et al. [27], when con-
ducting pre-trial simulations for the Matchpoint trial,
looked at six dose-toxicity scenarios over four dose levels;
these included two scenarios where the MTD (the dose
with an expected risk of DLT equal to 40%) was located
between two dose levels (Fig. 4).
The pre-trial simulation studies should be conducted
following recommended best practices [62, 63]:
 Create a detailed simulation plan, including expected
setup time, resources required, and overall time
needed to obtain results [64, 65];
 Record the random seed used, to allow replication;
 Generate a wide range of scenarios to investigate;
 Specify the number of simulation replications
needed to reduce variability in the operating
characteristics. Although there is no ideal number,
the larger the number of simulations, the lower the
variability in results;
 Run all competing designs (including a 3 + 3 design)
across all simulation scenarios to compare the
operating characteristics of interest.
In addition to simulations, we can assess the model rec-
ommendations based on a possible set of trial data. We can
calculate in advance every feasible sequence of doses result-
ing from different DLT/non-DLT responses from patients
in the next few cohorts; these are known as dose transition
pathways [51]. The trial team can generate dose transition
pathways to see if the design exhibits undesirable behaviour,
such as not stopping the trial despite observing excessive
toxicity at low doses. The design may then be recalibrated
to provide dose transition pathways that clinicians and the
trial team are happy with. Yap et al. [51] describe how they
used dose-transition pathways to design the Viola trial. Fig-
ure 5 illustrates the trial design process in its entirety.
The iterative structure shows the discussions that are
required to decide on different aspects of the design,
and how and when they should be evaluated.
Finalising the design
Once the trial design has been agreed, the pre-trial simu-
lations should be documented, detailing the set-up specifi-
cations, which designs were compared under which
scenarios, and an easily interpretable summary of the de-
sign’s main features. This report can be included in the
protocol appendix or statistical analysis plan, or can be a
Fig. 4 Dose-toxicity scenarios explored in the Matchpoint trial. Red
line indicates TTL of 40%
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separate report that is formally acknowledged in the
protocol and statistical analysis plan and stored in the trial
master file. We provide a general description of the CRM
that can be used in trial protocols in Additional file 1:
Appendix C. The target audiences for the simulation
report are internal project teams and the research eth-
ics committee. For some dose-finding trials, simulation
reports may need to be submitted to regulators.
Trial conduct
Once the trial design has been confirmed and the trial
has started, the recommended dose level for the next
patient is determined as follows:
i) Obtain available data on the patients currently in
the trial;
ii) Update the estimated DLT probabilities at each
dose using the model;
iii) Write a brief report detailing the model’s dose
recommendation, along with estimates of DLT
probabilities at all doses and any other quantities of
interest; and
iv) If necessary, hold a meeting of the dose setting
committee (DSC), or safety review committee
(SRC), to formally decide whether to use the
model’s recommendation or recommend a different
dose (based on additional non-DLT toxicity data).
The DSC is made up of researchers, clinicians, and
Fig. 5 Flowchart of the trial design process using the CRM
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members of the trial management group. The
committee members attend dose decision meetings
in person or via teleconference, and advise how the
trial should proceed based on the safety data ac-
crued during the trial. Dose transition pathways can
be computed for one or more future cohorts [51] to
aid the DSC in their recommendations.
Interim trial results should be reported to assist the DSC
in decision-making. The results of interest fall into two cat-
egories: observed trial data, such as the grades and types of
adverse event experienced by each patient and the number
of adverse events that are classed as DLTs; and probabilistic
results inferred from the dose-toxicity model.
Report contents
Observed trial data results can be presented in simple fre-
quency tables. A table of all observed adverse events as
rows, with toxicity grades as columns, should be popu-
lated by the number of patients that experienced each ad-
verse event of a particular grade. For example, if using the
National Cancer Institute’s Common Terminology
Criteria for Adverse Events (NCI CTCAE) grading system
[66], low grades (e.g., 1 and 2) can be combined, as may
higher grades (3 and 4) if, say, any grade 3 or higher ad-
verse event is classed as a DLT. Any observed fatalities,
classified as grade 5 adverse events, must be reported
separately. Some trial publications divide these data across
dose levels, providing a more accurate breakdown of
which doses adverse events were observed at. For prob-
abilistic results, we recommend providing the estimated
(mean/median) probability of DLT per dose level with
some measurement of variation or confidence/credible
interval, either in a table or graph.
Software for updating models and producing reports
Several software packages have been developed for de-
signing, conducting, and analysing dose-finding studies
using rule-based designs and the CRM (Table 2). These
include software packages for popular statistical pro-
grams (e.g., R and Stata), as well as stand-alone pro-
grams with point-and-click user interfaces, some of
which are freely available online. Many of these pack-
ages include tools for generating skeletons and dose
Table 2 Software for designing, simulating, and conducting dose-finding trials using rule-based designs and the CRM
Name Host/Institution Software/
Stand-
alone
Free/
Commercial
Rule-based/
Model-
based
Description
bcrm [88] CRAN R Free Both Design, run, and simulate trials using the CRM and 3 + 3
design
dfcrm [18] CRAN R Free Model-
based
Design, run, and simulate trials using the CRM and Time-
to-event CRM
crmPack [89] CRAN R Free Both Design, run, and simulate trials using the CRM (includes
other model-based designs, joint toxicity-efficacy
modelling)
crm [90] IDEAS (RePEc) Stata Free Model-
based
Run a single trial using the CRM
MoDEsT [91] Lancaster University Stand-
alone
(online)
Free Model-
based
Design, run, and simulate trials using the CRM
Bayesian CRM for
phase I trials [92]
University of Virginia Stand-
alone
(online)
Free Model-
based
Design, run, and simulate trials using the CRM
AplusB [93] MRC Biostatistics Unit,
University of Cambridge
Stand-
alone
(online)
Free Rule-based Compute exact operating characteristics for 3 + 3 and
other rule-based designs
Center for Quantitative
Sciences Calculator [94]
Vanderbilt University Stand-
alone
(online)
Free Both Simulate trials using the CRM (uses bcrm [88] and dfcrm
[18]) and other designs (rule-based/model-based)
CRMSimulator [95] MD Anderson Cancer
Center, University of
Texas
Stand-
alone
Free Model-
based
Simulate trials using the CRM
FACTS [96] Berry Consultants Stand-
alone
Commercial Both Design program for phase I trials using the CRM, plus
fixed and adaptive designs for phase II trials
ADDPLAN [97] ICON PLC Stand-
alone
Commercial Both Design, simulate, and analyse trials using the CRM
(includes methods for dose-response modelling)
Abbreviations: CRAN Comprehensive R Archive Network, CRM Continual Reassessment Method, FACTS Fixed and Adaptive Clinical Trial Simulator, MoDEsT Model-
based Dose-Escalation Trials, RePEc Research Papers in Economics
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labels under different dose-toxicity models and for
simulating and conducting trials using likelihood-based
and Bayesian methods. Help files are available for all
programs, and most are provided with examples.
Results
To provide a sensible starting design that may be cali-
brated following simulation studies and investigator dis-
cussions, we recommend choosing initial trial
parameters from the following options:
 Dose levels: between 4 and 8 levels;
 TTL: between 5% and 50%, but appropriate for the
expected adverse events listed in the DLT definition,
disease type and patient population;
 Prior guess of MTD: this dose should have prior
estimate of DLT risk close or equal to the TTL;
 Model: power or logistic; one parameter is sufficient,
but two parameter models are also used;
 Skeleton: use appropriate data from previous studies
and clinical experience to specify prior DLT risks all
doses; if not possible for all, consider specifying for
some key doses (e.g. prior MTD, lowest dose,
highest dose) and interpolate for levels in between. If
challenging to do this, given prior guess of MTD
and model choice, use the skeleton calibration
approach of Lee and Cheung [36];
 Inference: if a run-in stage is required before using
the model, likelihood or Bayesian methods can be used;
otherwise, a Bayesian approach in a one-stage design
can be used with either informative or uninformative
priors depending on the availability of suitable data;
 Cohort size: between 1 and 3 patients, but no more
than maximum number of available patients divided
by number of dose levels;
 Safety rules: no-dose skipping, start at dose no larger
than prior MTD, possibly the lowest dose;
 Stopping rules: terminate the trial for safety if there
is high chance (e.g. at least 90%) that the risk of
DLT at the lowest dose level is greater than the
TTL. Consider adding additional stopping criteria if
warranted by simulations and investigators.
Though recommendations from literature and experi-
ence are useful, case studies of published CRM trials are
valuable learning tools. We present two real trials that
used the CRM to identify the MTD of new cancer ther-
apies; one trial using a one-stage Bayesian approach and
another using a two-stage likelihood-based approach.
Bayesian CRM: ssHHT in AML
Lévy et al. [67] conducted a dose-finding study to find the
MTD of subcutaneous semi-synthetic homoharringtonine
(ssHHT) given intravenously in patients with advanced
acute myeloid leukaemia. Investigators planned to examine
five dose levels of ssHHT (0.5, 1, 3, 5, and 6mg/m2/day),
and specified a TTL of 33%, or 0.33. The investigators
chose a Bayesian CRM approach for the trial [68]. They
used a one-parameter logistic model and placed an expo-
nential prior distribution with a mean of 1 (and therefore
variance of 1) on the slope parameter and fixed the inter-
cept to be 3 (see Table 1). The prior for the slope param-
eter and fixed intercept were chosen after extensive
simulation studies to ensure the model was suitable [per-
sonal correspondence with study statistician]. They based
their skeleton (0.05, 0.10, 0.15, 0.33, and 0.50) on data from
China, where a non-synthetic form of the molecule was
used in practice. Dose labels were calculated using the
skeleton and prior mean estimate of the model parameter.
During the trial, the posterior estimates for the prob-
ability of DLT at each dose were computed, and the next
cohort received the dose with an estimated probability
of a DLT closest to the TTL. Patients were dosed in
three-person cohorts. The trial was to be terminated if
adding another cohort of three patients would not
change the estimate of the probability of a DLT at the
MTD by more than 5%.
After observing no DLTs in the first cohort, who received
0.5mg/m2/day, the model recommended the largest dose
(6mg/m2/day) for the next cohort. The investigators were
not comfortable with this escalation and chose to dose the
next cohort at 3mg/m2/day. After one DLT out of three pa-
tients at 3mg/m2/day, the next three patients were recom-
mended to receive 5mg/m2/day. The trial was terminated
after treating 18 patients, as per the pre-specified stopping
rule. Twelve patients received 5mg/m2/day, four of whom
experienced DLTs. At the end of the trial, the posterior esti-
mates of DLT probabilities were 0.06, 0.12, 0.17, 0.36, and
0.53. As 5mg/m2/day had a posterior estimate probability
of a DLT closest to the TTL, it was selected to be the MTD
(Fig. 6). Although we cannot say if fewer or more patients
would have been recruited to the trial under a 3 + 3 design,
the 3 + 3 design would have taken longer to reach the
MTD level (nine patients dosed below the MTD, rather
than six), and fewer patients would have been dosed at the
MTD level during the trial (no more than six patients).
Likelihood-based CRM: rViscumin in solid tumours
Paoletti et al. [69] conducted a trial to find the MTD of
the lectin rViscumin given intravenously in patients with
solid tumours. The dose levels to be investigated were 10,
20, 40, 100, 200, 400, 800, and 1600 ng/kg, with additional
dose increases of 800 ng/kg. DLT was defined as any
haematological grade 4 or non-haematological grade 3+
adverse event as per the NCI Common Toxicity Criteria
Version 2 [70], with the exclusion of nausea, vomiting, or
fever that could be rapidly controlled. The TTL was fixed
at 20%, or 0.20.
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The investigators implemented a two-stage likelihood-
based CRM design, with a one-parameter power model for
the dose-toxicity relationship. In the first stage, individual
patients were dosed at increasing dose levels. The starting
dose of 10 ng/kg was taken as 1% of the MTD in dogs. If a
grade 2+ non-DLT adverse event was observed in one of
these patients, another two patients were given that dose. If
none of the three patients experienced a DLT, the first stage
escalation continued. The model-based design stage was
initiated when the first DLT was observed. Using a dose
skeleton that was specified after the first DLT occurred (as
it was not required during the first stage), dose labels were
created for each dose. The estimates for the probability of a
DLT at each dose were calculated using maximum likeli-
hood methods and the next patient was given the dose with
an estimated DLT probability closest to the TTL, subject to
the constraint that no untested dose level could be skipped.
Patients were dosed in single-patient cohorts, since low in-
cidence of toxicity was expected, and the current patient
was fully observed before the next patient was allocated to a
dose. Although they did not state a planned sample size, the
trial was to be terminated if the probability that the next five
patients would be given the same dose level exceeded 90%.
The first 10 patients, dosed at 10, 20, 40, 100, 200, 400,
800, 1600, 2400, and 3200 ng/kg respectively, had no mod-
erate toxicity or DLTs. Patient 11, dosed at 4000 ng/kg,
experienced a DLT (grade 3 asthenia), and from here the
CRM design was used to make dose escalation/de-escala-
tion recommendations, with oversight from the SRC.
After estimating the model parameter, dose level 10 (3200
ng/kg), which had an estimated probability of DLT equal
to 18%, was selected for patient 12. After patient 26 expe-
rienced a DLT (grade 3 transaminitis) at 4800 ng/kg, the
SRC met to discuss dose allocation for patient 27. Upon
review, the SRC recoded the DLT observed in patient 11
to a non-DLT, as it was resolved the same day it occurred.
The SRC decided, given the revised estimates of DLT
probability and the type of DLT observed, to dose patient
27 at the escalated dose of 5600 ng/kg (probability of DLT
estimated as 21%). The trial was terminated after 37 pa-
tients were treated, 3 of whom had DLTs (patient 26 at
4800 ng/kg, patients 35 and 37 at 6400 ng/kg; all grade 3
transaminitis). The MTD was deemed to be 5600 ng/kg,
with an estimated probability of DLT of 0.16 (95% confi-
dence interval = (0.06, 0.44)). Figure 7 shows the conduct
of the trial and the final estimates for the probability of a
DLT with 95% confidence intervals. If a 3 + 3 design were
used in this trial, at least 36 patients would have been
dosed below the MTD. By using a two-stage CRM design,
the sample size was reduced and the initial data from pa-
tients 1–10 were also used in dose-escalation decisions.
Discussion
The CRM was first published in 1990. Its use in clinical
trials, although increasing over time, remains low. Rogatko
et al. [4] found 20 (1.6%) of 1235 phase I trials published
between 1991 and 2006 used model-based designs, while
a recent review found 92 (5.4%) of 1712 trials published
between 2008 and 2014 used model-based designs, 59
(64.1%) of which used the CRM [5]. The infrequent use of
the CRM is at odds with the mounting evidence that the
CRM is better than the 3 + 3 design, both for estimating
the MTD and for assigning more patients in the trial at
the MTD. The example trials presented here show the
Bayesian and likelihood-based CRM both dosed fewer
patients at levels below the eventual MTDs than the 3 + 3
design, and dosed most of the patients recruited to the
trial at or close to the MTD.
To encourage the uptake of the CRM in practice, we
have provided a structured framework for designing,
conducting and analysing phase I dose-finding trials
using the CRM. We have separated the design stage into
its core steps and, where possible, offered recommen-
dations based on experience, the literature, simulation
studies and published trials. There are several soft-
ware packages and online applications available with
supporting help files that can be used to design and
Fig. 6 Results from the dose-finding trial of ssHHT in patients with
advanced acute myeloid leukaemia [63] a) Trial conduct and DLTs
observed. b) Final posterior mean estimates of DLT probabilities and
95% credible intervals (2.5th and 97.5th percentiles).
Wheeler et al. BMC Medical Research Methodology           (2019) 19:18 Page 11 of 15
simulate trials using the CRM, and we have also pro-
vided template text and tables that may be used in
trial protocols and reports. However, the primary
asset for designing a phase I trial with a model-based
design is a trained statistician. Whilst more time and
effort may be required during trial set-up than for a
rule-based design, particularly for the first CRM study
a trial team embarks on, these costs will decrease
over time as experience increases. With respect to the
authors’ host institutions, there are no standard
operating procedures (SOPs) in place for designing
CRM trials. Currently it is the expertise and judge-
ment of the statistician(s), as well as the collaborative
relationship between the study statistician(s) and clinical
investigators, that are used to design the trial. The work
by Yap et al. on designing the Viola trial (which used a
CRM design) is a clear example of this in action [51].
However, with time, it may be the case that formal SOPs
are introduced.
In this paper, we have only dealt with the simple case of
a binary DLT endpoint that is fully observable in all pa-
tients. However, the CRM can be modified to deal with
more nuanced endpoints and more complex trials, such
as time-to-event outcomes [71–73], multiple toxicity
grades [74, 75], joint toxicity and efficacy outcomes [76,
77], combinations of drugs [7], dose- and schedule-finding
[78, 79], and patient covariates [80]. Like trials that use
rule-based designs, dose-expansion cohorts can be added
at the estimated MTD in a CRM-designed trial to obtain
additional data on efficacy and tolerability [81–87].
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